NDAINJECTIONINJECTABLE
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Quadramet is a radiopharmaceutical injection containing Samarium SM-153 lexidronam pentasodium, approved in 1997 for palliative treatment of bone metastases. It is a bone-seeking radiopharmaceutical that delivers targeted radiation to osteoblastic bone lesions, reducing pain in cancer patients with skeletal metastases.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect declining team size and transition to lifecycle management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero current job postings linked to Quadramet reflect its mature, LOE-approaching stage with minimal hiring activity. Roles on this product typically focus on maintaining existing market presence and managing transition to generic competition rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on QUADRAMET at Remedy Plan Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.